Results 231 to 240 of about 108,133 (341)

Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea. [PDF]

Curr Opin Pulm Med
D'Annibale DA, Mimoto M, McCowen KC, Malhotra A.   +3 more
europepmc   +1 more source

GLP‐1 Receptor Agonists for the Prevention of New‐Onset Heart Failure: A Systematic Review and Meta‐Analysis of Placebo‐Controlled Randomized Clinical Trials

Obesity Reviews, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) improve outcomes in heart failure (HF) with preserved ejection fraction. Whether GLP‐1 RA prevent new‐onset HF in Type 2 diabetes or obesity requires further investigation. Methods We performed an updated meta‐analysis of randomized placebo‐controlled trials (RCT) of treatment ...
João Sérgio Neves, Carolina B. Lobato, Ana Rita Leite, Catarina Vale, Francisco Vasques‐Nóvoa, Francisca Saraiva, Adelino Leite‐Moreira, Jens J. Holst, João Pedro Ferreira   +8 more
wiley   +1 more source

Improved cardiovascular outcomes with glucagon-like peptide-1 receptor agonists - what is the role of weight reduction? [PDF]

Cardiovasc Endocrinol Metab
Jacob S, Eckel RH, Krentz AJ.
europepmc   +1 more source

The Double‐Edged Sword of Gestational Insulin Resistance: Navigating Maternal Adaptation and Its Risks for Pregnancy and Offspring Health

Obesity Reviews, EarlyView.
ABSTRACT Although much research focuses on the effects of hyperglycemia during pregnancy on maternal and offspring health, this narrative review specifically centers on the role of insulin resistance (IR) in pregnancy complications and offspring long‐term health.
Runyu Du, Fei Wang, Ling Li, Qiuyue Wang
wiley   +1 more source

Inflammatory Bowel Disease in Children and Young People Living With Overweight or Obesity: A Critical Narrative Review

Obesity Reviews, EarlyView.
ABSTRACT Inflammatory bowel disease is a chronic inflammatory disorder affecting the gastrointestinal tract. It mainly comprises of Crohn's disease and ulcerative colitis. Its global prevalence has risen simultaneously with overweight and obesity among children and young people over the last decades.
Razan Algarni, Efstathia Papada, Adrian Brown   +2 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction. [PDF]

Cardiooncology
Scalia IG, Ibrahim R, Abdelnabi M, Pham HN, Farina JM, Pietri MP, Lee KS, Tamarappoo BK, Arsanjani R, Ayoub C.   +9 more
europepmc   +1 more source

Re: Commentary on “Impact of diabetes mellitus and grip strength on postoperative outcomes in older patients undergoing cancer surgery: A single‐center retrospective cohort study”

Journal of Diabetes Investigation, EarlyView.
Tian Ruan
wiley   +1 more source

Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence

Obesity Reviews, EarlyView.
ABSTRACT Next‐generation incretin therapies, including semaglutide and tirzepatide, have transformed obesity and Type 2 diabetes management. However, evidence‐based nutritional strategies to support safe and effective use of these agents remain limited.
Marie Spreckley, Cara F. Ruggiero, Adrian Brown   +2 more
wiley   +1 more source

Glucagon-like Peptide-1 Receptor Agonists in Heart Failure: Mechanisms, Evidence and Identifying Optimal Candidates. [PDF]

Card Fail Rev
Abdelhamid M, Abdrabou MM, Faris E, El Kafas S, Hosny M, Hassan A.   +5 more
europepmc   +1 more source